KO’d By Allergy Failure, Circassia Looks To Respiratory Pipeline For Second Wind
Executive Summary
Circassia is shifting its focus on its respiratory portfolio following the disappointing Phase III results of its cat allergy drug in June, which saw the company’s share price plummet by more than 60%.